A vast majority of the transplant recipients are cytomegalovirus (CMV)-seropositive (R+). We sought to assess variables predictive of CMV infection, specifically in R+ liver transplant recipients. Study patients comprised 182 consecutive liver transplant recipients who survived at least 14 days afte
Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation?
β Scribed by Jong Man Kim; Sung-Joo Kim; Jae-Won Joh; Choon Hyuck David Kwon; Sanghyun Song; Milljae Shin; Ju Ik Moon; Gaab Soo Kim; Seung Heui Hong; Suk-Koo Lee
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 304 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.22249
No coin nor oath required. For personal study only.
β¦ Synopsis
Cytomegalovirus (CMV) infections contracted after liver transplantation put patients at an increased risk of morbidity and mortality. We analyzed the effects of CMV infection by time of onset, mortality, and graft failure risk factors in liver recipients who were CMV donor-positive/recipient-positive (DΓΎ/RΓΎ). We reviewed 618 medical records for consecutive adult liver transplant cases. CMV pp65 antigenemia assays to determine patient CMV status were administered monthly. The incidences of CMV infection and disease were 55.7% (344 of 618 records) and 5.5% (34 of 618 records), respectively. The differences in patient survival and graft failure rates for CMV-infected and CMV-uninfected patients were not significant (P ΒΌ 0.707 and P ΒΌ 0.973), but the rates were lower in patients with CMV disease than in CMV-uninfected patients (P ΒΌ 0.005 and P ΒΌ 0.030, respectively). The recurrence of hepatitis B virus and hepatocellular carcinoma, hepatic dysfunction, infection, numerous pp65-staining cells, and CMV disease were found to be the risk factors for mortality and graft failure in CMV DΓΎ/RΓΎ adult liver transplant patients. In conclusion, the occurrence of CMV disease, and not asymptomatic CMV infection, was a risk factor for mortality and graft failure in adult liver transplant recipients with CMV DΓΎ/RΓΎ.
π SIMILAR VOLUMES
## Key Points 1. Cytomegalovirus (CMV) is a common infection after liver transplantation and manifests as an asymptomatic infection or clinically as CMV syndrome (fever and myelosuppression) or tissue-invasive CMV disease. 2. The most common risk factor for CMV disease is donor positivity and recip
The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient-negative/donor-positive (RΟͺ/DΟ©) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institutio
C ytomegalovirus (CMV) is a ubiquitous herpes virus that, together with human herpesvirus type 6 (HHV-6) and HHV-7, belongs to the Ξ²-herpesvirus family. Like other herpes viruses, CMV establishes lifelong latent infections. Infection with CMV is common in all populations, but is infrequently associa
## Abstract The presence of antiβendothelial cells (AECA), smooth muscle (SMA), antinuclear (ANA) and antimitochondrial (AMA) autoantibodies, and liver/kidney microsomal antibody type 1 (LKM1) was investigated retrospectively in sera of liver transplant patients and correlated with cytomegalovirus
We thank Jain et al. for their interest and correspondence regarding our recently published study. 1 The authors note that the incidence of cytomegalovirus (CMV) disease in our retrospective study was much lower than that reported by others. As acknowledged in our article, we did not use routine sur